Selecting the right tools to build your pluripotent stem cell based disease models

The presentation outlines a case study in establishing the operational space of a Grignard reaction in a series of continuous stirred tank reactors (CSTRs).

In biotherapeutic discovery, traditional hybridoma and phage approaches now both contend with and are complemented by NGS and synthetic strategies to meet candidate timelines measured in weeks rather than years.

Plasmid DNA products are one of the most common non-viral vectors, frequently used in both in vivo and ex vivo gene therapies. As a result, they can be utilised as drug substance (DS)/drug product (DP), intermediate or starting material.

De-Risky Business: Assessing Biotherapeutic Off-Target and On-Target Liabilities Toxicity failures caused by off-target or unintended on-target liabilities are a leading cause of attrition in clinical and preclinical programs. Given the effort, cost, and technical limitations of traditional biopharmaceutical de-risking strategies, there is a need for a robust and scalable approach that can be rapidly applied to the discovery phases of therapeutic programs. Join us for this exciting new GEN Webinar, where our panel of experts will discuss new approaches to de-risking lead selection of antibodies and other biotherapeutics.